Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Kezar Life Sciences, Inc. (KZR)
Last kezar life sciences, inc. earnings: 8/7 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE)Detailed poster with additional results will be presented during EULAR 2019 in Madrid SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that data from the first two cohorts of an open-label dose escalation trial of KZR-616 in patients with systemic lupus erythematosus (SLE) will be featured in a poster presentation at the European League Against Rheumatism (EULAR) 2019 annual meeting taking place in Madrid, Spain June 12-15. The full abstract, which is published on EULAR’s conference website, features preliminary results from the first two cohorts of the Phase 1b portion of the MISSION trial (Modulator
Show less
Read more
Impact Snapshot
Event Time:
KZR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZR alerts
High impacting Kezar Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
KZR
News
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
- Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
KZR
Earnings
- 11/12/24 - Beat
KZR
Sec Filings
- 12/3/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/14/24 - Form SCHEDULE
- KZR's page on the SEC website